Wockhardt Shares Hit 52-Week High After CDSCO Approval

Wockhardt shares witnessed a massive rally on Friday, surging more than 17% to touch a fresh 52-week high after the company received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for its breakthrough urinary tract infection (UTI) antibiotic in India. The strong market reaction reflects growing investor confidence in the company’s pharmaceutical pipeline and future growth potential.

The stock climbed as much as 17.45% during intraday trading to hit a new yearly high of ₹2,080 per share on the National Stock Exchange (NSE). The rally comes amid strong momentum in the pharmaceutical sector and positive sentiment surrounding the company’s latest drug approval. Despite touching a low of ₹1,086.70 earlier in March 2026, the stock has staged a sharp recovery over recent weeks.

Over the past week, Wockhardt shares have gained nearly 31%, while the stock has advanced around 48% in the last month. On a year-to-date basis, the company has delivered gains of approximately 45%, making it one of the strong-performing pharma stocks in recent sessions.

The sharp rise in the share price follows the company’s announcement that it received approval from India’s drug regulator for the import and marketing of Zaynich, an injectable antibiotic developed using the combination of Zidebactam and Cefepime. The company described the drug as a first-in-class breakthrough antibiotic discovered and developed in India.

According to the company, the approval has been granted for the treatment of complicated urinary tract infections (cUTI) in adult patients aged 18 years and above. The drug will also be used for cases involving pyelonephritis and Gram-negative bacteremia, which are considered serious bacterial infections requiring advanced antibiotic treatment.

The approval was backed by results from the ENHANCE-1 Phase 3 clinical trial, an international, randomised, double-blind study designed to evaluate the safety and effectiveness of Zaynich compared to meropenem in patients suffering from complicated urinary tract infections. The successful outcome of the trial played a major role in securing regulatory clearance.

Wockhardt has also expanded its regulatory efforts globally. The company has already submitted a New Drug Application (NDA) in the United States and a Marketing Authorisation Application (MAA) in the European Union for Cefepime/Zidebactam. Both applications are currently under review by regulatory authorities.

The injectable antibiotic has additionally received several important recognitions from the United States Food and Drug Administration (US FDA), including priority review, fast track status, and Qualified Infectious Disease Product (QIDP) designation. These recognitions were granted for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia.

Apart from regulatory progress, the company also reported strong financial performance for the fourth quarter of FY26. Wockhardt posted a consolidated net profit of ₹166 crore during the March quarter, compared to a net loss of ₹25 crore in the same period last year. The turnaround in profitability further boosted investor sentiment.

Revenue from operations increased 30% year-on-year to ₹965 crore during the quarter under review, compared to ₹743 crore in the corresponding quarter of the previous financial year. The company also reported strong operational performance, with EBITDA rising 147% year-on-year to ₹196 crore from ₹79 crore in Q4 FY25.

Market experts believe the latest drug approval, improving financial performance, and strong momentum in the company’s research pipeline could continue supporting positive sentiment in the stock. Investors are closely watching further regulatory developments in the US and European markets, which could act as additional growth triggers for the pharmaceutical major.

With a market capitalisation of more than ₹32,948 crore, Wockhardt is increasingly attracting investor attention as the company strengthens its position in the global antibiotics segment through innovation-driven pharmaceutical research and advanced drug development initiatives.